These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

277 related items for PubMed ID: 30284023

  • 1. Lisinopril versus lisinopril and losartan for mild childhood IgA nephropathy: a randomized controlled trial (JSKDC01 study).
    Shima Y, Nakanishi K, Sako M, Saito-Oba M, Hamasaki Y, Hataya H, Honda M, Kamei K, Ishikura K, Ito S, Kaito H, Tanaka R, Nozu K, Nakamura H, Ohashi Y, Iijima K, Yoshikawa N, Japanese Study Group of Kidney Disease in Children (JSKDC).
    Pediatr Nephrol; 2019 May; 34(5):837-846. PubMed ID: 30284023
    [Abstract] [Full Text] [Related]

  • 2. Efficacy and safety of lisinopril for mild childhood IgA nephropathy: a pilot study.
    Nakanishi K, Iijima K, Ishikura K, Hataya H, Awazu M, Sako M, Honda M, Yoshikawa N, Japanese Pediatric IgA Nephropathy Treatment Study Group.
    Pediatr Nephrol; 2009 Apr; 24(4):845-9. PubMed ID: 18825420
    [Abstract] [Full Text] [Related]

  • 3. Low-dose combination therapy with temocapril and losartan reduces proteinuria in normotensive patients with immunoglobulin a nephropathy.
    Horita Y, Tadokoro M, Taura K, Suyama N, Taguchi T, Miyazaki M, Kohno S.
    Hypertens Res; 2004 Dec; 27(12):963-70. PubMed ID: 15894837
    [Abstract] [Full Text] [Related]

  • 4. Randomized controlled trial of mycophenolate mofetil in children, adolescents, and adults with IgA nephropathy.
    Hogg RJ, Bay RC, Jennette JC, Sibley R, Kumar S, Fervenza FC, Appel G, Cattran D, Fischer D, Hurley RM, Cerda J, Carter B, Jung B, Hernandez G, Gipson D, Wyatt RJ.
    Am J Kidney Dis; 2015 Nov; 66(5):783-91. PubMed ID: 26209543
    [Abstract] [Full Text] [Related]

  • 5. Combination therapy with or without warfarin and dipyridamole for severe childhood IgA nephropathy: an RCT.
    Shima Y, Nakanishi K, Kaku Y, Ishikura K, Hataya H, Matsuyama T, Honda M, Sako M, Nozu K, Tanaka R, Iijima K, Yoshikawa N, Japanese Pediatric IgA Nephropathy Treatment Study Group.
    Pediatr Nephrol; 2018 Nov; 33(11):2103-2112. PubMed ID: 29987456
    [Abstract] [Full Text] [Related]

  • 6. Design of combination angiotensin receptor blocker and angiotensin-converting enzyme inhibitor for treatment of diabetic nephropathy (VA NEPHRON-D).
    Fried LF, Duckworth W, Zhang JH, O'Connor T, Brophy M, Emanuele N, Huang GD, McCullough PA, Palevsky PM, Seliger S, Warren SR, Peduzzi P, VA NEPHRON-D Investigators.
    Clin J Am Soc Nephrol; 2009 Feb; 4(2):361-8. PubMed ID: 19118120
    [Abstract] [Full Text] [Related]

  • 7. Combined therapy of enalapril and losartan attenuates histologic progression in immunoglobulin A nephropathy.
    Tanaka H, Suzuki K, Nakahata T, Tsugawa K, Konno Y, Tsuruga K, Ito E, Waga S.
    Pediatr Int; 2004 Oct; 46(5):576-9. PubMed ID: 15491387
    [Abstract] [Full Text] [Related]

  • 8. Randomized controlled clinical trial of corticosteroids plus ACE-inhibitors with long-term follow-up in proteinuric IgA nephropathy.
    Manno C, Torres DD, Rossini M, Pesce F, Schena FP.
    Nephrol Dial Transplant; 2009 Dec; 24(12):3694-701. PubMed ID: 19628647
    [Abstract] [Full Text] [Related]

  • 9. Abelmoschus manihot - a traditional Chinese medicine versus losartan potassium for treating IgA nephropathy: study protocol for a randomized controlled trial.
    Li P, Chen YZ, Lin HL, Ni ZH, Zhan YL, Wang R, Yang HT, Fang JA, Wang NS, Li WG, Sun XF, Chen XM.
    Trials; 2017 Apr 11; 18(1):170. PubMed ID: 28395659
    [Abstract] [Full Text] [Related]

  • 10. Treatment effects of Chinese medicine (Yi-Qi-Qing-Jie herbal compound) combined with immunosuppression therapies in IgA nephropathy patients with high-risk of end-stage renal disease (TCM-WINE): study protocol for a randomized controlled trial.
    Li S, Li JP.
    Trials; 2020 Jan 06; 21(1):31. PubMed ID: 31907076
    [Abstract] [Full Text] [Related]

  • 11. Efficacy and safety of angiotensin-converting enzyme inhibitors or angiotensin receptor blockers for IgA nephropathy in children.
    Vaz de Castro PAS, Bitencourt L, Pereira BWS, Lima AQR, Hermida HS, Moreira Neto CR, Mestriner MD, Simões E Silva AC.
    Pediatr Nephrol; 2022 Mar 06; 37(3):499-508. PubMed ID: 34686915
    [Abstract] [Full Text] [Related]

  • 12. Add-on angiotensin receptor blockade with maximized ACE inhibition.
    Agarwal R.
    Kidney Int; 2001 Jun 06; 59(6):2282-9. PubMed ID: 11380832
    [Abstract] [Full Text] [Related]

  • 13. Long-term results of a randomized controlled trial in childhood IgA nephropathy.
    Kamei K, Nakanishi K, Ito S, Saito M, Sako M, Ishikura K, Hataya H, Honda M, Iijima K, Yoshikawa N, Japanese Pediatric IgA Nephropathy Treatment Study Group.
    Clin J Am Soc Nephrol; 2011 Jun 06; 6(6):1301-7. PubMed ID: 21493743
    [Abstract] [Full Text] [Related]

  • 14. Risk factors for persistent proteinuria after a 2-year combination therapy for severe childhood IgA nephropathy.
    Kamei K, Nakanishi K, Ito S, Ishikura K, Hataya H, Honda M, Nozu K, Iijima K, Shima Y, Yoshikawa N, Japanese Pediatric IgA Nephropathy Treatment Group.
    Pediatr Nephrol; 2015 Jun 06; 30(6):961-7. PubMed ID: 25487669
    [Abstract] [Full Text] [Related]

  • 15. Dual renin-angiotensin system blockade at optimal doses for proteinuria.
    Laverman GD, Navis G, Henning RH, de Jong PE, de Zeeuw D.
    Kidney Int; 2002 Sep 06; 62(3):1020-5. PubMed ID: 12164886
    [Abstract] [Full Text] [Related]

  • 16. Treatment with low-dose angiotensin-converting enzyme inhibitor (ACEI) plus angiotensin II receptor blocker (ARB) in pediatric patients with IgA nephropathy.
    Yang Y, Ohta K, Shimizu M, Nakai A, Kasahara Y, Yachie A, Koizumi S.
    Clin Nephrol; 2005 Jul 06; 64(1):35-40. PubMed ID: 16047643
    [Abstract] [Full Text] [Related]

  • 17. Comparison of antiproteinuric effects of two different combination therapies in children with IgA nephropathy.
    Yagi K, Okada M, Yanagida H, Kuwajima H, Ikeda M, Sugimoto K, Takemura T.
    Clin Exp Nephrol; 2003 Dec 06; 7(4):270-4. PubMed ID: 14712355
    [Abstract] [Full Text] [Related]

  • 18. Aldosterone breakthrough during therapy with angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers in proteinuric patients with immunoglobulin A nephropathy.
    Horita Y, Taura K, Taguchi T, Furusu A, Kohno S.
    Nephrology (Carlton); 2006 Oct 06; 11(5):462-6. PubMed ID: 17014562
    [Abstract] [Full Text] [Related]

  • 19. Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers for IgA nephropathy.
    Dillon JJ.
    Semin Nephrol; 2004 May 06; 24(3):218-24. PubMed ID: 15156527
    [Abstract] [Full Text] [Related]

  • 20. Low-dose losartan therapy reduces proteinuria in normotensive patients with immunoglobulin A nephropathy.
    Shimizu A, Takei T, Uchida K, Tsuchiya K, Nitta K.
    Hypertens Res; 2008 Sep 06; 31(9):1711-7. PubMed ID: 18971549
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.